@ADurbinLab

Clinician-scientist Pediatric Oncologist focusing on chemical epigenetics & transcriptional circuitries. Better treatments, less toxicity. @stjuderesearch

 Memphis, TN
Joined April 2020
  • Tweets1.1K
  • Following993
  • Followers1.3K
57Media
So excited to work with @JunQiLab on this important study!
Dana-Farber News
@DanaFarberNewsOct 21
New research published in @JExpMed from @DanaFarber’s @JunQiLab and collaborators reveals that AKT inhibitors synergize with EP300 degraders to suppress osteosarcoma growth in vitro and in vivo. These agents positively combine across cancer cells in a manner dependent on control of protein synthesis. ➡️bit.ly/4z13y9G
1
1
7
440
Researchers identified a potential therapeutic vulnerability in a subset of osteosarcoma. In preclinical models, combining EP300 degradation with AKT inhibition slowed tumor growth and prolonged survival. The findings suggest a potential path toward more personalized treatment. bit.ly/3U3DwDt

Combination therapy reveals potential vulnerability in aggressive osteosarcoma

Explore new St. Jude research uncovering that degrading EP300 and inhibiting AKT in combination may synergize to treat sensitive metastatic osteosarcomas.

stjude.org
6
18
1,537
Online today in @JExpMed, doi.org/10.1084/jem.20251898 TLDR: a genetically-defined group of osteosarcoma is sensitive to the EP300 PROTAC JQAD1, due to a balance between degradation and resynthesis by the ribosome. Read on for deets...

Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300

Here, Delahunty et al. identify that EP300 controls the growth of AKT-dysregulated osteosarcoma cells by regulating expression of state-specific genetic de

rupress.org
1
4
19
1,222
more replies
This work sets the stage for future work testing more drug-like EP300 degraders with AKT inhibitors in osteosarcoma and indeed, across many, many other types of cancer.
1
40
We are grateful to the funders of this work for their support: @theNCI @NIH @StJudeResearch @StJude @hopeonwheels @CureSearch @RallyFoundation @ALSFNews @TheVFoundation @curingcancer and the Pediatric Dependencies Accelerator.
38
Looking for a post-doctoral fellowship in computational biology, focused on answering important questions in childhood cancer? Why wait? Apply now! This position bridges the brilliant Brian J. Abraham lab computation with experimentation in the Adam Durbin lab @StJudeResearch.
1
3
8
1,091
Competitive candidates have a computational background, as described in the application post below. Come join us and make a difference! talent.stjude.org/careers/Jo… @TheAbraLab @StJudeResearch @MolOnc_StJude

Postdoctoral Research Associate - Computational Sciences

Position Responsibilities:This grant-funded position is part of an inter-institutional, interdisciplinary effort to deconvolve the roles of chromatin-modifying enzymes and complexes in...

talent.stjude.org
1
113
How “specific” are the inhibitors we use? In @nchembio, Sterling and Holtsmark et al reveal a dual inhibitory role for the clinical agent zavondemstat! Findings with implications for target and patient selection in trials, discussed by Drs Ali Nezhady and McKay-Corkum.
1
10
408
more replies
And our commentary here: rdcu.be/M1KFeo4zzJfa This perhaps explains some of the exceptional activity in #neuroblastoma. @theNCI @RallyFoundation @ALSFNews @DamonRunyon @thesgconline
1
1
93
@StJudeResearch @MolOnc_StJude
44
Load more